MPH, Health Policy and Administration, North Carolina School of Public Health
University of North Carolina, Chapel Hill, NC
Elizabeth Andrews, PhD, is Vice President Emeritus at RTI-HS. She continues to advise on epidemiology research programs that evaluate drug safety and compliance with risk minimization programs. These include prospective patient cohort studies, surveys, and studies using large existing databases. Until recently, she served as Vice President of Pharmacoepidemiology and Risk Management, serving as principal investigator or senior advisor for many projects across multiple therapeutic and geographic areas.
Previously, Dr. Andrews held the position of Vice President, Worldwide Epidemiology, at GlaxoSmithKline, where she initiated the first pharmaceutical pregnancy registry, the Acyclovir Pregnancy Registry, and multiple registries for other medications. She played an active role in the US policy debate that shaped HIPAA, testifying multiple times in Congress on the value of patient-level data in observational research. She began her career in the pharmaceutical industry at Burroughs Wellcome in 1982 and subsequently built a strong international epidemiology program at Glaxo Wellcome. Prior to joining Burroughs Wellcome, she managed the Statewide Regionalized Perinatal Care Program and directed the non-Medicaid health care reimbursement programs for the State Health Department of North Carolina.
Dr. Andrews is a Fellow and Past President of the International Society for Pharmacoepidemiology, and coeditor of Pharmacovigilance. She is an Adjunct Associate Professor at the University of North Carolina School of Public Health.